France Implements New Early Access Pathway For Innovative Medicines
Current Procedures Have Become Too Complex, Says Health Ministry
Reforms to the French early access processes will make reimbursement decisions more predictable and bring greater consistency into the medicinal product pathway says the French pharmaceutical industry body Leem. Others, though, say the system is too complicated and lacks clarity in a number of areas.
